1. Home
  2. CRBP vs HGLB Comparison

CRBP vs HGLB Comparison

Compare CRBP & HGLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CRBP

Corbus Pharmaceuticals Holdings Inc.

HOLD

Current Price

$7.91

Market Cap

190.3M

Sector

Health Care

ML Signal

HOLD

Logo Highland Global Allocation Fund

HGLB

Highland Global Allocation Fund

N/A

Current Price

$7.28

Market Cap

174.3M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CRBP
HGLB
Founded
2009
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
190.3M
174.3M
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
CRBP
HGLB
Price
$7.91
$7.28
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$45.50
N/A
AVG Volume (30 Days)
991.2K
61.2K
Earning Date
05-08-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,822,272.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$116.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
97.62
N/A
52 Week Low
$6.33
$7.14
52 Week High
$20.56
$10.64

Technical Indicators

Market Signals
Indicator
CRBP
HGLB
Relative Strength Index (RSI) 34.64 40.17
Support Level $7.62 $7.26
Resistance Level $8.54 $7.67
Average True Range (ATR) 0.74 0.11
MACD -0.26 -0.01
Stochastic Oscillator 26.45 30.86

Price Performance

Historical Comparison
CRBP
HGLB

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About HGLB Highland Global Allocation Fund

Highland Global Allocation Fund is a diversified, closed-end management investment company. The investment objective of the Fund is to seek long-term growth of capital and future income. The Fund seeks to achieve its investment objectives by investing in a portfolio of U.S. and foreign equity, debt, and money market securities. It may also invest in senior loans to domestic or foreign corporations, partnerships, and other entities that operate in a variety of industries and geographic regions.

Share on Social Networks: